Clinical Trial Update: An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi) [Phase 1]

View source ↗

Summary

This completed Phase 1 open-label trial evaluated the disposition of 400 mg [14C]-Iniparib and its effects on QT/QTc intervals in patients with advanced solid t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Iniparib (iparib)

Snippet

Sponsor: Sanofi | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED